Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arnaldo Torres

Rheumatology St Petersburg, FL Medical Doctor

NPI 1437132263 CMS profile 291240

620 10Th St N # 3C, St Petersburg, FL 33705

Open in the dashboard

General payments

$89,380

1,497 records reported · program years 2019–2025

Research payments

$2,853

Paid to them · 23 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$196,173 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Arnaldo Torres of St Petersburg, FL is reported in the CMS Open Payments database as having received $89,380 across 1,497 general payments and $2,853 in research payments paid to them. Separately, studies naming them as principal investigator received $196,173 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,342 249
2024 General $8,053 257
2023 General $13,073 224
2023 Research $1,295 9
2022 General $12,211 211
2021 General $5,866 212
2020 General $11,269 148
2019 General $17,565 196
2019 Research $1,559 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arnaldo Torres
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Arnaldo Torres were reported at $21,342. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Arnaldo Torres Rheumatology median Middle half National median
2019 $17,565 $744 $153–$2,687 $163
2020 $11,269 $462 $98–$2,027 $114
2021 $5,866 $531 $101–$2,153 $132
2022 $12,211 $627 $125–$2,303 $149
2023 $13,073 $741 $145–$2,524 $160
2024 $8,053 $830 $166–$2,660 $164
2025 $21,342 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $48,504 231 payments
  2. Amgen Inc. $9,492 333 payments
  3. Pfizer Inc. $9,400 90 payments
  4. Lilly USA, LLC $4,135 76 payments
  5. UCB, Inc. $2,715 85 payments
  6. Novartis Pharmaceuticals Corporation $2,509 158 payments
  7. Janssen Biotech, Inc. $2,465 169 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $1,582 17 payments
  9. Genzyme Corporation $1,039 30 payments
  10. AstraZeneca UK Limited $1,007 9 payments
  11. Other $6,533 299 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $44,350 28 payments
  2. Food and Beverage $29,376 1,410 payments
  3. Consulting Fee $9,820 5 payments
  4. Travel and Lodging $5,274 35 payments
  5. Education $560 19 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $34,663 152 payments
  2. XELJANZ $9,227 71 payments
  3. HUMIRA $5,119 41 payments
  4. SKYRIZI $4,567 12 payments
  5. TREMFYA $2,167 119 payments
  6. SAPHNELO $1,666 33 payments
  7. Prolia $1,649 87 payments
  8. Otezla $1,542 86 payments
  9. COSENTYX $1,388 105 payments
  10. KEVZARA $1,239 19 payments
  11. Other $18,284 1,138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,559 14 payments
  2. AbbVie, Inc. $1,295 9 payments

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

3,448

Median for Rheumatology: 1,511

Drug cost

$2,692,163

Median for Rheumatology: $1,139,948

Branded share of claims

26.3%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 50 $373,396
Enbrel Sureclick Etanercept Brand 32 $234,493
Cosentyx Sensoready (2 Pens) Secukinumab Brand 32 $231,899
Rinvoq Upadacitinib Brand 30 $220,353
Tremfya Guselkumab Brand 15 $206,615
Otezla Apremilast Brand 31 $146,975
Orencia Clickject Abatacept Brand 25 $145,827
Taltz Autoinjector Ixekizumab Brand 21 $144,853
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 13 $134,915
Cimzia (2 Pack) Certolizumab Pegol Brand 21 $133,211

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$343,357

Of which drugs: $238,890

Medicare patients

471

Average age 75

Services billed

32,955

370 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 54%
Ischemic heart disease 32%
Chronic kidney disease 29%
Depression 29%
COPD 25%
Diabetes 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 88 7,680 $157,150
Injection, methylprednisolone acetate, 1 mg J1010 Office 12 920 $96

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$2,625 30 —
TREMFYA
$793 15 —
COSENTYX
$413 32 —
BENLYSTA
$389 15 —
XELJANZ
$387 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

1,520 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record